Fundamentals-based quality & risk · not a recommendation
GPT Healthcare Ltd scores 71/100 (Quality) on the Orion Score — strong business quality (85), moderate growth (54), strong balance-sheet safety (77) and fair valuation (41). A fundamentals-based quality & risk score, not a buy/sell recommendation.
Risk checks
Forensic accounting
Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check
Technical / Momentum
Price Trend
64/100
Technical momentum companion — separate from the fundamentals-based Orion Score.
Unlock with Pro
Upgrade →Q4 FY2026
Revenue & Profit in ₹ Crores
| Quarter | Revenue | Net Profit | OPM | EPS |
|---|---|---|---|---|
| Q4 2026 | ₹126.37 | ₹14.57 | 13.0% | ₹1.78 |
| Q3 2026 | ₹120.16 | ₹9.37 | 11.3% | ₹1.14 |
| Q2 2026 | ₹118.91 | ₹10.6 | 13.4% | ₹1.29 |
| Q1 2026 | ₹107.11 | ₹7.68 | 10.4% | ₹0.94 |
| Q4 2025 | ₹101.4 | ₹12.89 | 15.6% | ₹1.57 |
Revenue & Profit in ₹ Crores (Yearly)
| Year | Revenue | Net Profit | EBITDA | OPM |
|---|---|---|---|---|
| FY 2025 | ₹406.45 | ₹49.92 | ₹90.91 | 16.5% |
| FY 2024 | ₹399.55 | ₹47.77 | ₹92.52 | 18.0% |
| FY 2023 | ₹360.39 | ₹39.01 | ₹79.32 | 16.5% |
| FY 2022 | ₹336.77 | ₹41.66 | ₹77.86 | 18.0% |
Top companies in the same sector by market cap
| Company | Mkt Cap | P/E | ROCE | ROE | D/E | OPM |
|---|---|---|---|---|---|---|
| GPTHEALTH ★ | ₹1,228 Cr | 29.06 | 14.82% | 16.32% | 0.34x | 12.99% |
| SUNPHARMA | ₹4,27,609 Cr | 37.32 | 15.73% | 14.72% | 0.06x | 18.90% |
| MAXHEALTH | ₹95,110 Cr | 66.21 | 11.94% | 14.33% | 0.32x | 22.56% |
| AUROPHARMA | ₹90,029 Cr | 25.94 | 12.55% | 9.93% | 0.21x | 15.11% |
| ABBOTINDIA | ₹57,724 Cr | 36.63 | 36.14% | 34.46% | 0.04x | 27.01% |
| AJANTPHARM | ₹41,836 Cr | 39.55 | 27.99% | 25.39% | 0.06x | 51.40% |
All values in ₹ Crores
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹384.25 | ₹345.52 | ₹326.76 | ₹323.22 |
| Equity | ₹247.85 | ₹218.49 | ₹165.36 | ₹158.18 |
| Total Debt | ₹35.3 | ₹30.54 | ₹82.36 | ₹101.56 |
| Cash | ₹1.66 | ₹1.69 | ₹6.6 | ₹8.27 |
| Net Debt | ₹11.64 | ₹10.73 | ₹58.07 | ₹87.25 |
| Working Capital | ₹4.57 | ₹2.95 | ₹-0.58 | ₹17.21 |
Q1 FY2027
Quarter-over-Quarter Trend
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Q1 FY2027 | 66.77% ↑ | 4.08% ↑ | 3.34% ↓ | 25.81% ↑ |
| Q3 FY2026 | 65.57% | 2.73% ↓ | 6.2% ↓ | 25.48% ↑ |
| Q2 FY2026 | 65.57% | 3.2% ↓ | 6.45% ↓ | 24.77% ↑ |
| Q1 FY2026 | 65.57% | 4.96% ↑ | 9.33% ↓ | 20.14% ↑ |
| Q4 FY2025 | 65.57% | 4.49% ↓ | 11.35% ↑ | 18.59% ↑ |
| Q3 FY2025 | 65.57% | 4.71% | 11.3% ↑ | 18.41% ↓ |
| Q2 FY2025 | 65.57% | 4.7% ↓ | 10.8% ↓ | 18.92% ↑ |
| Q1 FY2025 | 65.57% | 5.38% | 11.88% | 17.16% |
No recent corporate actions
3 mutual fund schemes
Ask: "Is GPT Healthcare Ltd stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation
Analyse with OrionGet free stock analysis, market insights, and investment ideas delivered to your inbox.
No spam. Unsubscribe anytime.